What is the role of alternative biomarkers for coronary heart disease?

Clinical Endocrinology

Volumn 75, Issue 3, 2011, Pages 289-293

  Garg, Abhimanyu ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; APOLIPOPROTEIN B; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN; D DIMER; FERRITIN; FIBRINOGEN; GELATINASE B; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 6; LEPTIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; ROSUVASTATIN; SERUM AMYLOID A; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

AGE; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; FAMILY HISTORY; GENDER; GENE LOCUS; GENETIC ASSOCIATION; GLUCOSE BLOOD LEVEL; HAZARD RATIO; HUMAN; HYPERTENSION; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPID METABOLISM; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; SCORING SYSTEM; SMOKING; SYSTOLIC BLOOD PRESSURE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY DISEASE; FIBRINOGEN; HOMOCYSTEINE; HUMANS; LIPOPROTEIN(A); PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 79961238924     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2011.04045.x     Document Type: Article

References (30)

1. Kannel, W.B., McGee, D., &, Gordon, T., (1976) A general cardiovascular risk profile: the Framingham Study. American Journal of Cardiology, 38, 46-51.
2. Stamler, J., Neaton, J.D., Garside, D.B., et al. (2005) Current status: six established major risk factors-and low risk. In:, M. Marmot, P. Elliott, eds. Coronary Heart Disease Epidemiology: From Aetiology to Public Health. Oxford University Press, London, UK, 32-70.
3. Lewington, S., Whitlock, G., Clarke, R., et al. (2007) Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet, 370, 1829-1839.
4. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). [see comments]. JAMA, 285, 2486-2497.
5. Grundy, S.M., Cleeman, J.I., Merz, C.N., et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Journal of the American College of Cardiology, 44, 720-732.
6. Pencina, M.J., D'Agostino Sr, R.B., Larson, M.G., et al. (2009) Predicting the 30-year risk of cardiovascular disease: the framingham heart study. Circulation, 119, 3078-3084.
7. Vasan, R.S., (2006) Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation, 113, 2335-2362. (Pubitemid 43947980)
8. Corson, M.A., (2009) Emerging inflammatory markers for assessing coronary heart disease risk. Current Cardiology Reports, 11, 452-459.
9. Greenland, P., Alpert, J.S., Beller, G.A., et al. (2010) 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 56, 2182-2199.
10. Helfand, M., Buckley, D.I., Freeman, M., et al. (2009) Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 151, 496-507.
11. U.S. Preventive Services Task Force (2009) Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine, 151, 474-482.
12. Musunuru, K., &, Kathiresan, S., (2010) Genetics of coronary artery disease. Annual Review of Genomics and Human Genetics, 11, 91-108.
13. Wald, N.J., Hackshaw, A.K., &, Frost, C.D., (1999) When can a risk factor be used as a worthwhile screening test? BMJ, 319, 1562-1565.
14. Vasan, R.S., (2009) Commentary: C-reactive protein and risk prediction-moving beyond associations to assessing predictive utility and clinical usefulness. International Journal of Epidemiology, 38, 231-234.
15. Pencina, M.J., D'Agostino Sr, R.B., D'Agostino Jr, R.B., et al. (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Statistics in Medicine, 27, 157-172; discussion 207-112. (Pubitemid 351193639)
16. Tziomalos, K., Athyros, V.G., Wierzbicki, A.S., et al. (2009) Lipoprotein a: where are we now? Current Opinion in Cardiology, 24, 351-357.
17. Gudnason, V., (2009) Lipoprotein(a): a causal independent risk factor for coronary heart disease? Current Opinion in Cardiology, 24, 490-495.
18. Rosenson, R.S., (2010) Lp-PLA(2) and risk of atherosclerotic vascular disease. Lancet, 375, 1498-1500.
19. Thompson, A., Gao, P., Orfei, L., et al. (2010) Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet, 375, 1536-1544.
20. Buckley, D.I., Fu, R., Freeman, M., et al. (2009) C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 151, 483-495.
21. Ridker, P.M., Danielson, E., Fonseca, F.A., et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine, 359, 2195-2207.
22. Wang, T.J., (2010) Multiple biomarkers for predicting cardiovascular events: lessons learned. Journal of the American College of Cardiology, 55, 2092-2095.
23. Cohen, J.C., Boerwinkle, E., Mosley Jr, T.H., et al. (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. New England Journal of Medicine, 354, 1264-1272.
24. Lawlor, D.A., Harbord, R.M., Timpson, N.J., et al. (2008) The association of C-reactive protein and CRP genotype with coronary heart disease: findings from five studies with 4,610 cases amongst 18,637 participants. PLoS ONE, 3, e3011.
25. Zacho, J., Tybjaerg-Hansen, A., Jensen, J.S., et al. (2008) Genetically elevated C-reactive protein and ischemic vascular disease. New England Journal of Medicine, 359, 1897-1908.
26. Kim, H.C., Greenland, P., Rossouw, J.E., et al. (2010) Multimarker prediction of coronary heart disease risk: the Women's Health Initiative. Journal of the American College of Cardiology, 55, 2080-2091.
27. Blankenberg, S., Zeller, T., Saarela, O., et al. (2010) Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation, 121, 2388-2397.
28. Schunkert, H., Konig, I.R., Kathiresan, S., et al. (2011) Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nature Genetics, 43, 333-338.
29. Peden, J.F., Hopewell, J.C., Saleheen, D., et al. (2011) A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nature Genetics, 43, 339-344.
30. Wang, F., Xu, C.Q., He, Q., et al. (2011) Genome-wide association identifies a susceptibility locus for coronary artery disease in the Chinese Han population. Nature Genetics, 43, 345-349.